Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Atossa Therapeutics, Inc. Common Stock

ATOS

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.85 – $2.08
Volume 36,406
Market cap $19M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$19.26M
Price / earnings
—
Price / book
0.89×
Price / sales
—
EV / sales
—
EV / EBITDA
0.04×

Profitability

Earnings per share
-$3.47
Return on assets
-131.03%
Return on equity
-159.41%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.35×
Quick ratio
4.71×
Cash ratio
4.37×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$35.29M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ATOS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.52M$3.8M$5.09M$5.28M$3.88M$3.54M$3.26M$3.75M
Research and development$3.38M$4.9M$4.78M$6.16M$5.37M$5.5M$4.16M$3.4M
Total operating expenses$5.9M$8.69M$9.87M$11.44M$9.25M$9.04M$7.41M$8.86M
Operating income-$5.9M-$8.69M-$9.87M-$11.44M-$9.25M-$9.04M-$7.41M-$8.86M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$5.64M-$8.49M-$9.59M-$10.94M-$8.69M-$8.42M-$6.72M-$6.35M
Income taxes$0$0$0$0$0$0$0$0
Net income-$5.64M-$8.49M-$9.59M-$10.94M-$8.69M-$8.42M-$6.72M-$6.35M
Net income attributable to common shareholders-$5.64M-$8.49M-$9.59M-$10.94M-$8.69M-$8.42M-$6.72M-$6.35M
EBITDA-$5.9M-$8.69M-$9.87M-$11.43M-$9.25M-$9.04M-$7.41M-$7.15M
Basic earnings per share-$0.56-$0.95-$1.11-$1.27-$1.01-$0.98-$0.78-$0.75
Diluted earnings per share-$0.56-$0.95-$1.11-$1.27-$1.01-$0.98-$0.78-$0.75

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.

Benzinga

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics reported Q1 2026 results with total operating expenses of $9.9 million, up $2.5 million year-over-year. The company advanced its lead candidate (Z)-endoxifen across oncology and rare disease indications, securing FDA Orphan Drug Designation for DMD and Rare Pediatric Disease designations for both DMD and McCune-Albright Syndrome. The company strengthened its clinical leadership team and presented encouraging preclinical data for (Z)-endoxifen in DMD at the MDA conference.

GlobeNewswire Inc.

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

Institutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising cancer treatments with strong clinical data and FDA support, positioning themselves for potential M&A activity as major pharma companies seek differentiated assets.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 2, 20261-for-15reverse split
Apr 20, 20181-for-12reverse split
Aug 26, 20161-for-15reverse split